Loading…
BioXcel Therapeutics, Inc. is projected to decline to $0.7392 by 2027, a -10% move from its current price of $0.8175. BTAI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.7603 | $0.8162 | $0.8762 | -0.16% |
| Jul 14 | $0.7372 | $0.8149 | $0.9009 | -0.31% |
| Jul 15 | $0.7196 | $0.8137 | $0.92 | -0.47% |
| Jul 16 | $0.705 | $0.8124 | $0.9362 | -0.62% |
| Jul 17 | $0.6922 | $0.8111 | $0.9505 | -0.78% |
| Jul 18 | $0.6807 | $0.8099 | $0.9635 | -0.93% |
| Jul 19 | $0.6703 | $0.8086 | $0.9755 | -1.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6703 | $0.8086 | $0.9755 | -1.09% |
| Week 2 | $0.6134 | $0.7998 | $1.04 | -2.17% |
| Week 3 | $0.5716 | $0.7911 | $1.09 | -3.23% |
| Week 4 | $0.5376 | $0.7825 | $1.14 | -4.28% |
| Week 5 | $0.5087 | $0.774 | $1.18 | -5.33% |
| Week 6 | $0.4834 | $0.7655 | $1.21 | -6.36% |
| Week 7 | $0.4609 | $0.7572 | $1.24 | -7.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. It markets IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, and it also develops its neuroscience candidate BXCL501, an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trials for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder. Its immune-oncology candidate BXCL701, an investigational oral innate immune activator, has completed Phase 1b/2a trials for aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
The company also engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has potential to address apathy and aggression in dementia. BioXcel Therapeutics was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BioXcel Therapeutics, Inc. (BTAI) is a healthcare company focused on neuroscience and immuno-oncology through AI-enabled drug development. It has a current price of $0.8022 and a market cap of $24.77M, with a market rank of 4823.
A major floor 50.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.9% away) — a key level to hold.
The nearest ceiling, 72.5% above — a clean break opens room to run.
A major ceiling 111.6% above — clearing it would confirm fresh momentum.
Key BTAI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BTAI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9196 | Sell | $0.9324 | Sell |
| MA 10 | $1.15 | Sell | $1.05 | Sell |
| MA 20 | $1.18 | Sell | $1.13 | Sell |
| MA 50 | $1.18 | Sell | $1.19 | Sell |
| MA 100 | $1.28 | Sell | $1.32 | Sell |
| MA 200 | $1.64 | Sell | $2.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.71 | Neutral |
| Stoch RSI (14) | 5.37 | Buy |
| CCI (20) | -168.82 | Sell |
| Williams %R (14) | -97.37 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -35.08 | Sell |
| Bollinger %B (20,2) | 0.00 | Neutral |
| Stochastic %K (14) | 2.63 | Buy |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 18.63 | Buy |
| Momentum (10) | -0.43 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 0.71 | Buy |
| ADX (14) | 20.97 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is Neutral, with RSI14 at 30 and the stock trading within a defined range. The SMA50 is $1.19 and the SMA200 is $1.66, offering some overhead resistance. The stock shows a near-term support level at $0.802 and a resistance level at $1.41, while the 30-day range spans $0.4906 to $1.31. Annualized volatility is very high at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.802 | $0.8175 | $0.9593 | 0% | Neutral | |
| $0.5362 | $0.7392 | $1.10 | -10% | Neutral | |
| $0.4332 | $0.6347 | $1.01 | -22% | Bearish | |
| $0.3511 | $0.5418 | $0.9033 | -34% | Bearish | |
| $0.5121 | $0.8284 | $1.44 | +1% | Neutral | |
| $0.5642 | $0.954 | $1.71 | +17% | Neutral | |
| $0.5046 | $0.8899 | $1.65 | +9% | Neutral | |
| $0.4731 | $0.8689 | $1.65 | +6% | Neutral | |
| $0.4143 | $0.7915 | $1.55 | -3% | Neutral | |
| $0.4013 | $0.797 | $1.59 | -3% | Neutral | |
| $0.4984 | $1.11 | $2.43 | +35% | Bullish | |
| $0.9911 | $2.20 | $5.07 | +169% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.802 | $0.8175 | $0.995 | +0.00% |
| August 2026 | $0.618 | $0.7489 | $0.9454 | -8.39% |
| September 2026 | $0.5768 | $0.7088 | $0.9135 | -5.35% |
| October 2026 | $0.5948 | $0.74 | $0.9702 | +4.39% |
| November 2026 | $0.5941 | $0.7468 | $0.9933 | +0.92% |
| December 2026 | $0.5609 | $0.7118 | $0.9593 | -4.68% |
Click any year to see its month-by-month BTAI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BioXcel Therapeutics, Inc.'s 2026 outlook centres on $0.8175, within a $0.802 to $0.9593 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BTAI could reach as high as $1.10, with a base case around $0.7392 and support toward $0.5362 — roughly -10% from $0.8175. Price action looks broadly range-bound.
Expect BTAI to range from $0.4332 to $1.01 through 2028. The $0.6347 average target implies a -22% move from current prices. That is -14% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
The BTAI price prediction for 2029 points to an average of $0.5418 (low $0.3511, high $0.9033) — a potential decline of -34% on today's $0.8175. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, BTAI is projected to trade between $0.5121 and $1.44, averaging $0.8284 — a potential gain of +1% from today's $0.8175. That is up +53% on the projected 2029 average. A consolidation phase looks the most probable path here.
BioXcel Therapeutics, Inc.'s 2031 outlook centres on $0.954, within a $0.5642 to $1.71 range. That is up +15% on the projected 2030 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2032, BTAI could reach as high as $1.65, with a base case around $0.8899 and support toward $0.5046 — roughly +9% from $0.8175. A consolidation phase looks the most probable path here.
Expect BTAI to range from $0.4731 to $1.65 through 2033. The $0.8689 average target implies a +6% move from current prices. That is -2% versus the projected 2032 average. Price action looks broadly range-bound.
The BTAI price prediction for 2034 points to an average of $0.7915 (low $0.4143, high $1.55) — a potential decline of -3% on today's $0.8175. A consolidation phase looks the most probable path here.
In 2035, BTAI is projected to trade between $0.4013 and $1.59, averaging $0.797 — a potential decline of -3% from today's $0.8175. That is up +1% on the projected 2034 average. Price action looks broadly range-bound.
BioXcel Therapeutics, Inc.'s 2040 outlook centres on $1.11, within a $0.4984 to $2.43 range. That is up +39% on the projected 2035 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BTAI could reach as high as $5.07, with a base case around $2.20 and support toward $0.9911 — roughly +169% from $0.8175. Momentum favours further upside here.
Investing $1,000 in BTAI today (≈ 1,223.24159 BTAI) could be worth
$2,694.22
+$1,694.22 (+169%) by 2050 · US Dollar
Based on the average projected BTAI price of $2.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BTAIwould be worth at today's price.
$1,000 invested in BTAI on Jul 10, 2025 (≈ 500 BTAI) would be worth
$408.75
-$591.25 (-59.1%) today · 0.41× · US Dollar
Based on a BTAI entry price of $2 vs. today's $0.8175.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.38 | $592.39 | -40.8% |
| 1 month ago | $1.09 | $750 | -25.0% |
| 3 months ago | $1.06 | $771.23 | -22.9% |
| 6 months ago | $2.02 | $404.7 | -59.5% |
| 1 year ago | $2 | $408.75 | -59.1% |
| All time (5.0y) ago | $416.96 | $1.96 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BTAI forecast.
Our base-case forecast reaches $1.60 around 2050.
Implied market cap at $1.60: $49.4M
The multi-year forecast shows a mixed but increasingly upside path beyond the near term. For 2026 the min is $0.802, avg $0.8022, max $0.9405 with ROI 0 and sentiment Neutral. In 2027 the min is $0.5273, avg $0.7271, max $1.08 with ROI -9.4 and Neutral sentiment, followed by 2028 years at min $0.4236, avg $0.6207, max $0.9861 with ROI -22.6 and Bearish sentiment, and 2029 with min $0.3435, avg $0.5302, max $0.8842 with ROI -33.9 and Bearish sentiment.
The year 2030 shows a modest improvement: min $0.5059, avg $0.8187, max $1.42 with ROI 2 and Neutral sentiment. Then 2031–2035 show varied returns, with 2031 min $0.5528, avg $0.9349, max $1.68 (ROI 16.5), 2032 min $0.4929, avg $0.8695, max $1.61 (ROI 8.4), 2033 min $0.4668, avg $0.8576, max $1.63 (ROI 6.9), 2034 min $0.4058, avg $0.7753, max $1.51 (ROI -3.4), and 2035 min $0.3923, avg $0.7791, max $1.56 (ROI -2.9). The outlook improves significantly in 2040, with min $0.4861, avg $1.08, max $2.37 and ROI 34.7 with Bullish sentiment, and in 2050, min $0.9735, avg $2.16, max $4.98 with ROI 169.7 and Bullish sentiment.
Tap a question to reveal the answer.
In 2030, Avg $0.8187, ROI 2; Min $0.5059, Max $1.42; sentiment Neutral.
Forecasts show a mix of near-term weakness (2027–2029 with negative ROIs) followed by a return toward positive levels (2030 with ROI 2) and substantial upside by 2040 (ROI 34.7) and 2050 (ROI 169.7). These are estimates and not guarantees.
Yes. The forecast shows a max above $1 in several years: 2027 max $1.08, 2030 max $1.42, 2040 max $2.37, and 2050 max $4.98.
Current price is $0.8022. The 30-day range is $0.4906 to $1.31.
2040: Avg $1.08, ROI 34.7, sentiment Bullish. 2050: Avg $2.16, ROI 169.7, sentiment Bullish.
BioXcel Therapeutics, Inc. Community Discussion
0Share your BioXcel Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.